Popular search terms:

Search Results Label

91 results found

Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.com/news/first-shipment-2021-22
Seqirus | About Influenza

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.com/expertise/influenza
EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic

A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day

https://www.seqirus.com/news/eu-flu-day-2021
The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.com/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children
Seqirus | Influenza Expertise

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com/expertise
Seqirus | Vaccine Technologies

Seqirus employs both egg and cell-based manufacturing systems to ensure the availability of our influenza vaccines. Learn more about our optimised technology.

https://www.seqirus.com/manufacturing/technologies
Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.com/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)

Seqirus appoints Roberta Duncan as new program lead to drive sa-mRNA technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.com/news/seqirus-invests-in-self-amplifying-messenger-rna-technology
Seqirus | Our Products

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.com/products
Seqirus | A World Leader in Influenza Vaccines

Learn more about how we're leveraging cutting-edge technology and proven expertise to develop influenza vaccines and respond to pandemic threats.

https://www.seqirus.com/